Infliximab
Treatment for Ulcerative Colitis
Typical Dosage: 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Effectiveness
80%
Safety Score
60%
Clinical Trials
118
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Time to Effect
2-6 weeks
Treatment Duration
Long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$22,500
Monitoring:$2,000
Side Effect Mgmt:$1,250
Total Annual:$25,750
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$40,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$36,785.71
Cost per Remission
$64,375
Comparison vs Conventional therapy
Cost Difference
+$20,000/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Infliximab Outcomes
for Ulcerative Colitis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+70%
Remission Rate
+40%
Common Side Effects
Infusion reactions
+12%
Infections (URI, UTI)
+20%
Headache
+12%
Antibody formation
+10%
Serious infections
+2%
Sources:
Active Clinical Trials
6 active trials recruiting for Infliximab in Ulcerative Colitis
Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab
NCT06614387NOT YET RECRUITINGPHASE3
60 participants
INTERVENTIONAL
Started: Oct 1, 2024
Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
NCT03765450ACTIVE NOT RECRUITING
18 participants
OBSERVATIONAL
San Diego, United States +2 more
Started: Dec 21, 2018
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
NCT05931458NOT YET RECRUITINGNA
94 participants
INTERVENTIONAL
Started: Jul 1, 2023
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT03596645ACTIVE NOT RECRUITINGPHASE3
84 participants
INTERVENTIONAL
San Francisco, United States +57 more
Started: Oct 29, 2018
Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
NCT06113913RECRUITINGPHASE4
275 participants
INTERVENTIONAL
Ghent, Belgium +14 more
Started: Apr 9, 2024
Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial
NCT07297069NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Hyderabad, India
Started: Jan 1, 2026
Completed Clinical Trials
10 completed trials for Infliximab in Ulcerative Colitis
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
NCT00336492COMPLETEDPHASE3
60 participants
INTERVENTIONAL
Birmingham, United States +26 more
Started: Sep 1, 2006
Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis
NCT02770040COMPLETEDPHASE4
138 participants
INTERVENTIONAL
Melbourne, Australia
Started: Jul 18, 2016
Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis
NCT01408810COMPLETEDPHASE4
21 participants
INTERVENTIONAL
Porto, Portugal
Started: Feb 1, 2011
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis
NCT00096655COMPLETEDPHASE3
364 participants
INTERVENTIONAL
Started: May 1, 2002
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis
NCT00036439COMPLETEDPHASE3
364 participants
INTERVENTIONAL
Started: Feb 1, 2002
A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis
NCT01551290COMPLETEDPHASE3
99 participants
INTERVENTIONAL
Beijing, China +6 more
Started: Apr 1, 2012
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis
NCT03679546COMPLETEDPHASE4
151 participants
INTERVENTIONAL
Amiens, France +18 more
Started: Jan 4, 2019
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
NCT00207688COMPLETED
505 participants
OBSERVATIONAL
Scottsdale, United States +101 more
Started: Aug 31, 2004
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
NCT03884439COMPLETED
428 participants
OBSERVATIONAL
Tokyo, Japan
Started: Mar 18, 2019
European Safety Registry in Ulcerative Colitis (P04808)
NCT00705484COMPLETED
2.24K participants
OBSERVATIONAL
Started: Jun 1, 2007
Showing 20 of 119 total trials